Skip to search formSkip to main contentSkip to account menu

PCH Regimen

Known as: Paclitaxel-Carboplatin-Herceptin Regimen 
A sequential regimen consisting of carboplatin and paclitaxel, followed by trastuzumab, used in the adjuvant setting for the treatment of HER-2/neu… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Pulmonary veno-occlusive disease (PVOD)/pulmonary capillary hemangiomatosis (PCH) is a rare form of pulmonary vascular disease… 
Review
2012
Review
2012
Trastuzumab (Herceptin®) is a humanized monoclonal antibody used in the treatment of breast cancer that overexpresses human… 
2011
2011
Pneumonitis is a rare but serious complication associated with paclitaxel and/or trastuzumab treatment. We report a 51-year-old… 
2011
2011
The current paper seeks to describe a small-scale hydro-energetic resources assessment method as a function of social and… 
Review
2010
Review
2010
Monoclonal antibodies (mAbs) have demonstrated considerable utility in the clinical treatment of cancer (Reichert et al. 2005… 
2004
2004
by Michelle A. Crowe, M.S. Washington State University May 2004 Chair: Sally E. Blank Breast cancer survivors are challenged by… 
2002
2002
HER2-positive status is the sole criterion for identifying patients with breast cancer for Herceptin® therapy, which has known… 
2002
2002
HER2-positive status is the sole criterion for identifying patients with breast cancer for Herceptin® therapy, which has known…